Helping Cancer Patients with Chronic Pain
Creating Ethical Shareholder Value

Invest with us

EIS Eligible Investment Opportunity

CBD Science has partnered with Crowd for Angels to provide a platform for raising £2 million at £0.50 a share on our EIS Approved Series A Funding raise. Together with Crowd for Angels, we are delighted to present your next investment opportunity.

01.

Solutions for patients with unmet medical needs.

We are pioneering research, development and the provision of access to commercially effective and affordable cannabinoid-based medicines specifically for treating patients suffering from cancer-related pain in the UK.

02.

Faster approach to delivering cannabis-based medicines.

We launched the first Real-World Evidence (RWE) peer-reviewed clinical trial in this domain. Supported by our already established & highly reputable Clinical Advisory Board.

03.

Endorsements & Strategic Relationships

We have received a number of highly sought-after endorsements and have partnerships with a number of leading oncology research centres across the UK, more information on these can be found under About Us.

Investor Portal Access

Access the CBD Science Investor Portal. Here you can find all the documents you may require for due diligence.

Our Mission

Generating shareholder value & helping suffering patients today.

The UK cannabinoid market is widely regarded to have high growth potential, with the legal market forecasted to be valued at £2.31 billion by 2024 (Prohibition Partners, 2021).

Comparable companies have already shown exceptional value and are trading at up to 80 times revenue.